Publication: Detection and significance of minimal residual disease in colorectal cancer
Loading...
Date
1999
Authors
Merrie, A.E.H. ; Yun, K. ; van Rij, A.M. ; McCall, J.L.
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Colorectal cancer (CRC) is one of the most
common causes of cancer death in the developed world.
Although the primary treatment for CRC is surgical,
disease relapse due to minimal residual disease (MRD)
following apparently curative surgery occurs in up to
fifty percent of patients. Most patients who develop
overt metastases beyond the regional lymph nodes
eventually die of the disease. At present adjuvant
chemotherapy is used to improve survival in patients
with metastases to regional lymph nodes demonstrated
by routine histopathology with no other evidence of
spread. The ability to identify metastatic disease at an
earlier stage could be of considerable benefit in directing
adjuvant therapy to patients at high risk of relapse who
are not identified by current methods. Several techniques
have been developed for the detection of MRD,
including immunohistochemical and molecular methods,
however their role in clinical practise is not yet
established. The purpose of this paper is to review these
techniques and their potential clinical use in the
management of CRC.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.